Piflufolastat F-18

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Prostate Imaging-PET: 18F-Piflufolastat (Pylarify).

Prostate Imaging-PET: 18F-Piflufolastat (Pylarify).

Journal: Journal of nuclear medicine technology

Published: March 09, 2026

Incidental Detection of PSMA Uptake in Lipomatous Hypertrophy of the Interatrial Septum.

Incidental Detection of PSMA Uptake in Lipomatous Hypertrophy of the Interatrial Septum.

Journal: Clinical nuclear medicine

Published: December 18, 2025

How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated.

How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated.

Journal: Journal of medicinal chemistry

Published: October 06, 2025

Brain and Spinal Leptomeningeal Metastases in Prostate Cancer Detected by PSMA PET and MRI Fusion.

Brain and Spinal Leptomeningeal Metastases in Prostate Cancer Detected by PSMA PET and MRI Fusion.

Journal: Clinical nuclear medicine

Published: September 21, 2025

PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions.

PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions.

Journal: Cancers

Published: September 16, 2025

Superior Diagnostic Yield of 18 F-rhPSMA-7.3 Compared With 18 F-DCFPyL PET/CT for the Detection of Recurrent Prostate Cancer.

Superior Diagnostic Yield of 18 F-rhPSMA-7.3 Compared With 18 F-DCFPyL PET/CT for the Detection of Recurrent Prostate Cancer.

Journal: Clinical nuclear medicine

Published: September 03, 2025

Radionuclides Landscape in Prostate Cancer Theranostics.

Radionuclides Landscape in Prostate Cancer Theranostics.

Journal: International journal of molecular sciences

Published: June 17, 2025

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 19, 2025

Different Appearances of Esophageal Squamous Cell Carcinoma in 18 F-PSMA PET/CT Versus 18 F-FDG PET/CT.

Different Appearances of Esophageal Squamous Cell Carcinoma in 18 F-PSMA PET/CT Versus 18 F-FDG PET/CT.

Journal: Clinical nuclear medicine

Published: October 30, 2024

Clinical Factors Associated With Suspicious 18F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL.

Clinical Factors Associated With Suspicious 18F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL.

Journal: The Journal of urology

Published: October 18, 2024

Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.

Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.

Journal: Clinical genitourinary cancer

Published: June 10, 2024

Evaluation of online teaching modules for PSMA PET interpretation.

Evaluation of online teaching modules for PSMA PET interpretation.

Journal: The Prostate

Published: March 14, 2024

Showing 1-12 of 23

Last Updated: 06/30/2026